香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告的全部或任何部份內 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 CNNC INTERNATIONAL LIMITED 中核國際有限公司 （於開曼群島註冊成立之有限公司） （股份代號：2302） 董事局會議通告 於本公告日期，董事局包括非執行董事暨主席：王成先生；執行董事暨行政總 裁：張義先生；非執行董事：吳戈先生及孫若凡先生；以及獨立非執行董事： 崔利國先生、陳以海先生及劉亞潔女士。 中核國際有限公司（「本公司」）之董事（「董事」）局（「董事局」）宣佈 本公司之董事局會議將於二零二五年八月二十六日（星期二）舉行，旨在（其 中包括）審議及批准本公司及其附屬公司截至二零二五年六月三十日止六個月 之中期業績公告及其發佈。 承董事局命 CNNC International Limited 中核國際有限公司 主席 王成 香港，二零二五年八月十四日 ...

致：香港交易及結算所有限公司 公司名稱: 中核國際有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02302 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 0.01 | HKD | | 10,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 1,000,000,000 | HKD | | 0.01 | HKD | | 10,000,000 | 本月底法定/註冊股本總額： HKD 10,000,000 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | FF ...

Core Viewpoint - 中核国际预计2025年半年度收入将显著增长，毛利和净利润也将实现大幅改善 [1] Financial Performance - 预计2025年半年度收入将达到不少于5.85亿港元，毛利将不少于1300万港元 [1] - 2024年同期收入和毛利分别为约640万港元 [1] - 预计2025年半年度股东应占净利润将不少于950万港元，扭转2024年半年度的净亏损约770万港元 [1] Business Growth Drivers - 收入增长主要得益于铀贸易业务交易量的大幅增加，绝大部分收入来自与独立第三方的天然铀贸易 [1] - 由于2024年下半年及2025年半年度现货铀价格相对稳定，集团能够在风险可控的前提下增加铀贸易业务 [1]

Group 1 - The core viewpoint of the article highlights that China Nuclear International (02302) has experienced a significant stock price increase of over 5%, currently trading at 3.9 HKD with a transaction volume of 1.6637 million HKD [1] - The company anticipates a substantial increase in revenue for the first half of 2025, projecting it to reach at least approximately 585 million HKD, compared to around 64 million HKD for the same period in 2024 [1] - The gross profit for the first half of 2025 is expected to rise to at least approximately 13 million HKD, a significant increase from the gross profit of around 640,000 HKD in the first half of 2024 [1] Group 2 - The company forecasts a turnaround from a net loss attributable to shareholders of approximately 7.7 million HKD in the first half of 2024 to a net profit of at least approximately 9.5 million HKD in the first half of 2025 [1] - This performance improvement is primarily attributed to a substantial increase in the trading volume of uranium business, with most revenue derived from natural uranium trading with independent third parties [1] - The stability of spot uranium prices in the second half of 2024 and the first half of 2025 has allowed the company to expand its uranium trading business with independent third parties while maintaining controllable risks [1]

Performance Updates - 开拓药业-B (09939.HK) has completed patient enrollment for the Phase III clinical trial of KX-826 solution for androgenetic alopecia in adult males in China [2] - 李氏大药厂 (00950.HK) has received approval from the National Medical Products Administration for Socazolimab to be used in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer in mainland China [2] - 恒瑞医药 (01276.HK) has received approval for clinical trials of SHR-8068 injection, Adebali monoclonal antibody injection, and Bevacizumab injection [2] - 恒瑞医药 (01276.HK) has also received approval to conduct clinical trials for HRS-5041, intended for prostate cancer treatment [2] - 深圳高速公路股份 (00548.HK) reported toll revenue of 106 million yuan for the outer ring project in June [2] - 大成生化科技 (00809.HK) has signed an EPC contract with Northeast Electric and Liaoning Electric for boiler renovation projects, with a maximum cost of 129.1 million yuan [2] - 小黄鸭德盈 (02250.HK) has signed a contract to develop an AI marketing system to diversify revenue sources [2] Buyback and Financing Activities - 威海银行 (09677.HK) plans to issue up to approximately 758 million domestic shares and 154 million H-shares, raising nearly 3 billion yuan [2] Financial Results - 香港电讯-SS (06823.HK) reported total revenue of 17.322 billion HKD for the first half, a year-on-year increase of 4%, with a net profit of 2.07 billion HKD, also up 4% [4] - 青岛银行 (03866.HK) reported operating revenue of 7.662 billion yuan for the first half, a growth of 7.5%, and a net profit of 3.065 billion yuan, up 16.05% [4] - 中国石油化工股份 (00386.HK) expects mid-term net profit to be between 20.1 billion and 21.6 billion yuan, a year-on-year decline of 39.5%-43.7% [4] - 汽车之家-S (02518.HK) reported total revenue of 3.212 billion yuan for the first half, a decrease of 7.75%, with a net profit of 772 million yuan, down 15.99% [4] - 绿茶集团 (06831.HK) issued a profit warning, expecting mid-term net profit to be between 230 million and 237 million yuan, a year-on-year increase of approximately 32%-36% [4] - 粤海置地 (00124.HK) issued a profit warning, expecting mid-term net profit to exceed 260 million HKD, turning from loss to profit [4] - 药师帮 (09885.HK) issued a profit warning, expecting mid-term net profit to exceed 70 million yuan [4] - 中国东方教育 (00667.HK) issued a profit warning, expecting mid-term net profit to grow by 45%-50% year-on-year [4] - 中核国际 (02302.HK) issued a profit warning, expecting mid-term revenue to increase to at least 585 million HKD, with net profit of at least 9.5 million HKD [4] - 大唐环境 (01272.HK) issued a profit warning, expecting mid-term net profit to decrease to between 350 million and 400 million yuan [4] - 长江生命科技 (00775.HK) issued a profit warning, expecting mid-term net loss of approximately 150 million HKD, turning from profit to loss year-on-year [4] - 延长石油国际 (00346.HK) issued a profit warning, expecting mid-term loss of approximately 27.9 million HKD [4]

Core Viewpoint - The company expects significant revenue growth in the first half of 2025, projecting at least approximately HKD 585 million, with a gross profit of at least approximately HKD 13 million, a substantial increase from the approximately HKD 6.4 million in revenue and gross profit for the same period in 2024 [1][2] Group 1: Financial Performance - The company anticipates a turnaround from a net loss attributable to shareholders of approximately HKD 7.7 million in the first half of 2024 to a net profit of at least approximately HKD 9.5 million in the first half of 2025 [1][2] - The increase in revenue and gross profit is primarily driven by a significant rise in uranium trading volumes, with most revenue coming from natural uranium trading with independent third parties [1] - The company expects stable spot uranium prices in the second half of 2024 and the first half of 2025, allowing for increased trading activities while managing risks [1] Group 2: Revenue and Costs - The gross profit is projected to increase by at least approximately HKD 13 million due to the rise in uranium trading volumes, alongside an increase in bank interest income of at least approximately HKD 3 million [2] - The company will not recognize any share of profits from an associated company in the first half of 2025, following the sale of a subsidiary in the second half of 2024, which previously contributed approximately HKD 15.6 million in profits [2] - Financial expenses are expected to decrease by at least approximately HKD 13 million in the first half of 2025, as the company did not utilize any bank financing during this period [2]

Core Viewpoint - The company, China Nuclear International (02302.HK), anticipates a significant increase in revenue and profit for the first half of 2025, driven primarily by a substantial rise in uranium trading volume, particularly with independent third parties [1][2]. Group 1: Financial Performance - The expected revenue for the first half of 2025 is projected to be at least HKD 585 million, a substantial increase from approximately HKD 6.4 million in the same period of 2024 [1]. - The gross profit for the first half of 2025 is expected to reach at least HKD 13 million, compared to approximately HKD 6.4 million in the first half of 2024 [1]. - The company forecasts a turnaround from a net loss attributable to shareholders of approximately HKD 7.7 million in the first half of 2024 to a net profit of at least HKD 9.5 million in the first half of 2025 [1]. Group 2: Business Operations - The increase in revenue and profit is primarily attributed to a significant rise in uranium trading volumes, with most revenue coming from natural uranium trading with independent third parties [1]. - The stable spot uranium prices in the second half of 2024 and the first half of 2025 have allowed the company to expand its uranium trading operations while managing risks effectively [1]. Group 3: Other Financial Factors - The increase in net profit is also supported by an increase in bank interest income of at least HKD 3 million [2]. - The company will not recognize any share of profits from an associate company in the first half of 2025, which contributed approximately HKD 15.6 million in the first half of 2024, due to the sale of an equity interest in a subsidiary [2]. - Financial expenses are expected to decrease by at least HKD 13 million in the first half of 2025, as the company did not utilize any bank financing during this period [2].

Core Viewpoint - The company expects significant revenue growth in the first half of 2025, projecting at least approximately HKD 585 million, with gross profit expected to increase to at least approximately HKD 13 million, compared to around HKD 6.4 million in the same period of 2024 [1] Group 1: Financial Performance - The company anticipates a turnaround from a net loss attributable to shareholders of approximately HKD 7.7 million in the first half of 2024 to a net profit of at least approximately HKD 9.5 million in the first half of 2025 [1] - The substantial increase in revenue and gross profit is primarily driven by a significant rise in uranium trading volumes, with most revenue coming from natural uranium trading with independent third parties [1][2] - The company expects a gross profit increase of at least approximately HKD 13 million and an increase in bank interest income of at least approximately HKD 3 million [2] Group 2: Operational Changes - The company will no longer benefit from any share of profits from an associated company in the first half of 2025, following the sale of an equity stake in a subsidiary in the second half of 2024, which contributed approximately HKD 15.6 million in the first half of 2024 [2] - Financial expenses are expected to decrease by at least approximately HKD 13 million in the first half of 2025, as the company did not utilize any bank financing during this period [2]

正面盈喜預告 本公告由中核國際有限公司（「本公司」，連同其附屬公司統稱「本集團」）根據聯交所 證券上市規則（「上市規則」）第13.09(2)條及《證券及期貨條例》（香港法例第571章）第 XIVA部項下的內幕消息條文（定義見上市規則）作出。 香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本公告的內容 概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告 的全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 CNNC INTERNATIONAL LIMITED 中核國際有限公司 （於開曼群島註冊成立之有限公司） （股份代號：2302） 股東及潛在投資者在買賣本公司證券時務請審慎行事。 承董事局命 CNNC International Limited 中核國際有限公司 主席 王成 香港，二零二五年七月三十一日 – 2 – 本公司董事（「董事」）局（「董事局」）謹此通知本公司股東（「股東」）和潛在投資者，經 初步審閱本集團截至二零二五年六月三十日止六個月（「2025年半年度」）之未經審核 綜合管理賬目及董事局目前掌握的資料，預期本集團於2025年半年度的收入 ...

港股核电股震荡走高，中核国际(02302.HK)涨近4%，中广核电力(01816.HK)涨超2%，中广核新能源 (01811.HK)涨超1%。 ...